CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (77,423)	$ (30,657)
Adjustments to reconcile net loss to cash flows from operating activities:
Depreciation and amortization	22,703	22,487
Share-based compensation expense	24,256	17,329
Deferred income taxes	(25,437)	(4,301)
Excess tax benefit from share-based compensation	(4,874)	(4,744)
Increase in the fair value of contingent consideration	(1,900)
Other non-cash charges	672	(145)
Changes in assets and liabilities:
Receivables	15,673	9,572
Inventory, prepaid expenses and other assets	(11,651)	3,021
Accounts payable and accrued expenses	(680)	(10,303)
Deferred revenue	(442)	(328)
Other long-term liabilities	1,889	146
Cash flows (used in) provided by operating activities	(57,214)	2,077
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions of property, plant and equipment	(12,009)	(10,710)
Proceeds from the sale of equipment	7	41
Investment in Reset Therapeutics, Inc.	(15,000)
Purchases of investments	(58,528)	(117,047)
Sales and maturities of investments	158,224	98,927
Cash flows provided by (used in) investing activities	72,694	(28,789)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the issuance of ordinary shares under share-based compensation arrangements	3,498	13,598
Excess tax benefit from share-based compensation	4,874	4,744
Employee taxes paid related to net share settlement of equity awards	(3,297)	(4,693)
Principal payments of long-term debt	(1,688)	(1,688)
Cash flows provided by financing activities	3,387	11,961
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	18,867	(14,751)
CASH AND CASH EQUIVALENTS - Beginning of period	181,109	224,064
CASH AND CASH EQUIVALENTS - End of period	199,976	209,313
Non-cash investing and financing activities:
Purchased capital expenditures included in accounts payable and accrued expenses	$ 3,099	$ 3,090